Alexandra Crane is a seasoned executive leader in life sciences and digital health, driving multi-million-dollar growth and innovation at TransPerfect Life Sciences. With extensive expertise in pharmaceutical outcomes, regulatory strategy, and global operations, she leads diverse international teams and spearheads transformative initiatives including AI-driven technology adoption and strategic M&A. Fluent in English and Spanish, Alexandra combines deep industry knowledge with strong cross-cultural communication skills to deliver exceptional business results and client value worldwide.

Dr. Trudy Vanhove is a seasoned biopharmaceutical executive and venture partner with nearly 30 years of experience leading drug development, regulatory strategy, and corporate growth across biotech and pharmaceutical companies. She has played a pivotal role in launching multiple FDA- and EMA-approved therapies and has a strong track record in building high-performing teams, driving strategic partnerships, and supporting financing efforts. Fluent in several languages and with extensive international experience, Dr. Vanhove brings a unique global perspective and a deep scientific and business acumen to board roles and investment opportunities in the biotech sector.

Susan Essumang is a seasoned clinical operations executive who merges scientific rigor with strategic leadership to drive high-impact pharmaceutical and biotech programs. Known for her patient-centric approach, Susan has led the development and regulatory success of globally recognized treatments, including Victoza®, Ozempic®, and Wegovy®, delivering billions in projected revenue. Her ability to align enterprise objectives with operational excellence has resulted in accelerated trial timelines, significant cost savings, and flawless regulatory inspections. With deep therapeutic expertise, a foundation in neuroscience and healthcare administration, and a commitment to innovation, Susan continues to shape the future of clinical research through data-driven insights and strategic execution.

Walt Johnston is a seasoned pharmaceutical executive known for driving transformative growth across global commercial operations, with a proven ability to launch and scale flagship brands in competitive therapeutic markets. His leadership spans over 30 years at industry powerhouses such as Pfizer, Astellas, Urovant Sciences, and Sumitomo Pharma, where he has consistently delivered above-market performance, integrated complex portfolios, and cultivated award-winning teams. With a deep commitment to integrity, collaboration, and innovation, Walt excels at aligning cross-functional strategy, optimizing organizational capability, and engaging stakeholders at every level—from boardrooms to the frontlines.

I'm excited to share my updated executive biography, which reflects over 20 years of experience in government relations, biotech policy, and strategic leadership. I'm actively exploring opportunities to serve on corporate and nonprofit boards where I can apply my skills to support growth, governance, and meaningful impact.

Dr. Michael E. Kuligowski, MD, PhD, MBA, is a globally recognized physician-executive with over four decades of leadership in dermatology, clinical development, and pharmaceutical strategy. With a distinguished career spanning Europe and the United States, he has led the development and approval of numerous dermatologic therapies, including Opzelura® for atopic dermatitis and vitiligo. Known for his scientific rigor, strategic foresight, and collaborative leadership, Dr. Kuligowski continues to influence the future of dermatologic innovation through executive roles, advisory board appointments, and pro-bono consulting in the life sciences sector.

Michael A. Pereira is a seasoned regulatory and quality executive with over three decades of experience guiding companies through the complex intersection of FDA compliance, global regulatory standards, and business operations. Known for his ability to build and remediate Quality Management Systems across diverse healthcare sectors—including drug, device, biologic, and combination products—Michael has led strategic initiatives for startups and global enterprises alike. With a rare ability to bridge technical and business teams, he brings clarity, structure, and strategic foresight to every challenge, earning a reputation as a trusted leader and advisor in highly regulated industries.

After 25+ years working at the intersection of science and strategy in cell and gene therapy, I’m excited to share a comprehensive look into my professional journey—from hands-on scientific innovation to leadership across CDMOs, biotech, and academic institutions. My passion lies in building high-impact teams, developing therapies that matter, and bridging ideas to execution. Here is my biography.

Excited to share my professional biography, highlighting my journey in global strategy, product launches, and commercialization within the pharmaceutical and biotech sectors. With over 25 years of experience, I've had the opportunity to work with extraordinary teams, driving growth and innovation across complex therapeutic areas. Here is my biography.